meta_pixel
Tapesearch Logo
Log in
Industry Focus

Healthcare: Should You Stick With Gilead Sciences?

Industry Focus

The Motley Fool

Interview, Money, Consumergoods, Business, Businessnews, Ceo, Technology, Investing, Stocks, Energy, Fool, Financial, Economy, Healthcare, News, Banking, Motley, Tech, Business News, Investments

4.6854 Ratings

🗓️ 6 June 2018

⏱️ 25 minutes

🧾️ Download transcript

Summary

Gilead Sciences has been one of biopharma's worst performers, and demand for its hepatitis C drugs has yet to bottom. Can its R&D program jump start investor optimism? Stocks: GILD

Transcript

Click on a timestamp to play from that location

0:00.0

Support for Industry Focus comes from our friends at Rocket Mortgage by Quickened Loans.

0:04.0

Home plays a big role in your life.

0:05.7

That's why Quicken Loans created Rocket Mortgage.

0:08.0

It lets you apply simply and understand the entire mortgage process fully so you can be confident

0:12.2

that you're getting the right mortgage for you.

0:13.0

for you.

0:14.0

To get started, go to rocket mortgage.com slash fool.

0:18.0

Welcome to Industry Focus, the podcast that dives into a different sector of the stock market every day.

0:24.0

Today is June 6th and this is the Wednesday Healthcare Edition of the show.

0:28.0

I'm your host Christine Harjus and I have Healthcare Specialist Todd Campbell on the line.

0:32.0

Welcome to the show Todd. and I have health care specialist Todd Campbell on the line.

0:32.8

Welcome to the show, Todd.

0:34.9

Hi, Christine.

0:36.4

It's going to be an interesting show today

0:37.9

for listeners because we're going to be talking

0:39.8

about probably one of the toughest things

0:42.2

for investors to do, which is sticking with stocks when they stumble right?

0:46.6

Absolutely yes so earlier today I had a great conversation with Jeff Fisher who is the lead advisor on Motley Fool Pro.

0:54.9

And we were talking about big biotech today.

0:58.4

In particular, he made this really good comparison to Big Pharma a couple decades ago where these stocks had been

1:04.6

darlings for so long until the patent cliff walloped them and newer treatments

1:09.6

came out and the stocks completely fell out of favor and now 20 years later it kind of looks like the market is getting the same

...

Please login to see the full transcript.

Disclaimer: The podcast and artwork embedded on this page are from The Motley Fool, and are the property of its owner and not affiliated with or endorsed by Tapesearch.

Generated transcripts are the property of The Motley Fool and are distributed freely under the Fair Use doctrine. Transcripts generated by Tapesearch are not guaranteed to be accurate.

Copyright © Tapesearch 2026.